Eprosartan Mesylate - CAS 144143-96-4
Catalog number: 144143-96-4
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C23H24N2O4S.CH4O3S
Molecular Weight:
520.62
COA:
Inquire
Targets:
Angiotensin Receptor
Description:
Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I1, Chilvers M, Reiz RJ. Can J Cardiol. 2004 Oct;20 Suppl C:11C-16C.
BACKGROUND: Isolated systolic hypertension (ISH) is a common and particularly poorly controlled form of hypertension.
2.Determination of eprosartan mesylate and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromato
Hacioğlu F1, Onal A. J Chromatogr Sci. 2012 Sep;50(8):688-93. doi: 10.1093/chromsci/bms037. Epub 2012 May 10.
Two new simple and selective assay methods have been presented for the analysis of eprosartan mesylate (EPR) and hydrochlorothiazide (HCT) in pharmaceutical formulations. The first method is based on first-derivative ultraviolet spectrophotometry with zero-crossing measurements at 246 and 279 nm for EPR and HCT, respectively. The assay was linear over the concentration ranges 3.0-14.0 µg/mL for EPR and 1.0-12.0 µg/mL for HCT. The quantification limits for EPR and HCT were found to be 1.148 and 0.581 µg/mL, respectively, while the detection limits were 0.344 µg/mL for EPR and 0.175 µg/mL for HCT. The second method involved isocratic reversed-phase liquid chromatography using a mobile phase composed of acetonitrile-10 mM phosphoric acid (pH 2.5) (40:60, v/v). Olmesartan was used as internal standard and the substances were detected at 272 nm. The linearity ranges were found to be 0.5-30 and 0.3-15.0 µg/mL for EPR and HCT, respectively. The limits of detection were found to be 0.
3.Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, pl
Punzi HA1, Punzi CF. J Hum Hypertens. 2004 Sep;18(9):655-61.
This was a double-blind, randomized, placebo-controlled multicenter, titration-to-effect study of eprosartan in patients > or =60 years of age with isolated systolic hypertension. The study consisted of a 3 to 5-week placebo run-in period, a 13-week double-blind treatment period (6-week titration with eprosartan 600-1200 mg/day, 3-week maintenance, 4-week combination therapy with hydrochlorothiazide/HCTZ 12.5 mg), and a follow-up period within 5-7 days of last treatment dose. Overall, 283 patients (placebo/P: 135; eprosartan /E: 148) were randomized [female patients-P: 55.6%, E:54.7%; white-P:66.7%, E:67.6%). Mean sitting systolic blood pressure (SitSBP) at baseline was comparable (P: 170+/-0.8 mmHg; E: 171+/-0.8 mm Hg). At monotherapy end point, eprosartan produced a significant reduction in SitSBP (E: 16.1 mmHg vs P: 8.4 mmHg; P<0.0001). In all, 57.4% of patients responded to eprosartan monotherapy. Among nonresponders, the addition of HCTZ resulted in a decrease in SitSBP from baseline (E: 21.
4.Quality by design: a systematic and rapid liquid chromatography and mass spectrometry method for eprosartan mesylate and its related impuriti
Kalariya PD1, Kumar Talluri MV, Gaitonde VD, Devrukhakar PS, Srinivas R. J Sep Sci. 2014 Aug;37(16):2160-71. doi: 10.1002/jssc.201301364. Epub 2014 Jul 10.
The present work describes the systematic development of a robust, precise, and rapid reversed-phase liquid chromatography method for the simultaneous determination of eprosartan mesylate and its six impurities using quality-by-design principles. The method was developed in two phases, screening and optimization. During the screening phase, the most suitable stationary phase, organic modifier, and pH were identified. The optimization was performed for secondary influential parameters--column temperature, gradient time, and flow rate using eight experiments--to examine multifactorial effects of parameters on the critical resolution and generated design space representing the robust region. A verification experiment was performed within the working design space and the model was found to be accurate. This study also describes other operating features of the column packed with superficially porous particles that allow very fast separations at pressures available in most liquid chromatography instruments.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Angiotensin Receptor Products


CAS 145040-37-5 Candesartan Cilexetil

Candesartan Cilexetil
(CAS: 145040-37-5)

Candesartan blocks the effects of angiotensin II at the angiotensin II type 1 (AT1) receptor. Candesartan cilexetil is a prodrug that is activated to candesarta...

CAS 141887-34-5 A81988

A81988
(CAS: 141887-34-5)

A81988 is a potent, orally active angiotensin I1 antagonist with a long duration of action whose pharmacological profile has established it as an important tool...

CAS 154512-46-6 L162441

L162441
(CAS: 154512-46-6)

An antagonist of Angiotensin type 1 receptor

CAS 136676-91-0 PD-123319 TFA salt

PD-123319 TFA salt
(CAS: 136676-91-0)

The ditrifluoroacetate salt form of PD-123319, a nonpeptide AT2R antagonist, could have potential effect against hypertension. It has already been discontinued ...

CAS 130663-39-7 PD123319

PD123319
(CAS: 130663-39-7)

PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

MK 996
(CAS: 157263-00-8)

MK-996, an imidazopyridine derivative, has been found to be an angiotensin receptor antagonist that was once developed in the treatment of hypertension by Merck...

CAS 144689-24-7 Olmesartan

Olmesartan
(CAS: 144689-24-7)

Olmesartan, a synthetic imidazole derivative, is a specific angiotensin II type 1 (AT1) receptor antagonist with antihypertensive effect. hAT1 receptors: IC50 =...

CAS 156001-18-2 Embusartan

Embusartan
(CAS: 156001-18-2)

Embusartan, an oxopyridine derivative, has been found to be an angiotensin II receptor antagonist that was once studied against hypertension by Bayer.

CAS 70806-55-2 trans-Tranilast

trans-Tranilast
(CAS: 70806-55-2)

Trans-Tranilast is an antiallergic drug used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.

Sacubitrilat
(CAS: 149709-44-4)

Sacubitrilat is one of the impurities of Sacubitril which has been found to be an endopeptidase inhibitor and be effective in the treatment of hypertension and ...

CAS 863031-21-4 Azilsartan Medoxomil

Azilsartan Medoxomil
(CAS: 863031-21-4)

Azilsartan Medoxomil is a potent angiotensin II type 1 (AT1) receptor antagonist that inhibits the RAAS, with an IC50 of 2.6 nM. It exhibits more than 10,000-fo...

CAS 139481-59-7 Candesartan

Candesartan
(CAS: 139481-59-7)

Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model

AVE 0991
(CAS: 304462-19-9)

AVE 0991 is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.

CAS 145216-43-9 Forasartan

Forasartan
(CAS: 145216-43-9)

Forasartan, a tetrazol derivative, has been found to be a angiotensin II receptor antagonist that could be effective against hypertension through influencing th...

CAS 247257-48-3 Fimasartan

Fimasartan
(CAS: 247257-48-3)

Fimasartan, also called as BR-A657, approved for the treatment of mild to moderate hypertension in South Korea, is a novel, non-peptide angiotensin II (Ang II) ...

Sparsentan
(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

CAS 477775-14-7 M 24

M 24
(CAS: 477775-14-7)

M 24 is the first selective AT2 receptor agonist (Ki 0.4nM and 10.000 nM for AT2 and AT1 respectively). M 24 effects against endothelial inflammation and leukoc...

CAS 863031-24-7 Azilsartan medoxomil monopotassium

Azilsartan medoxomil monopotassium
(CAS: 863031-24-7)

Azilsartan medoxomil monopotassium is an azilsartan prodrug and and an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM. It is...

CAS 124750-99-8 Losartan Potassium (DuP 753)

Losartan Potassium (DuP 753)
(CAS: 124750-99-8)

Losartan is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. It promotes vasodilatati...

CAS 127060-75-7 CGP-42112A

CGP-42112A
(CAS: 127060-75-7)

CGP-42112A, an angiotensin AT2 receptor agonist which could probably lead to the inhibition of ATPase and contraction of aortic rings in rabbit.

Chemical Structure

CAS 144143-96-4 Eprosartan Mesylate

Quick Inquiry

Verification code

Featured Items